Dupixent access in Saudi Arabia: the SFDA Personal Importation Program
How KSA patients legally obtain Dupixent (dupilumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Dupixent (dupilumab) is an interleukin-4 receptor alpha blocker approved by the US FDA across six type 2 inflammatory indications: atopic dermatitis from 6 months of age and up, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis in patients 1 year and older, prurigo nodularis, and COPD with type 2 inflammation. The Saudi Food and Drug Authority (SFDA) has registered Dupixent for the principal indications, and AbbVie's commercial partner Sanofi-Aventis distributes it through local agents. Even so, KSA families regularly use the SFDA Personal Importation Program (PIP) to bridge gaps that local registration alone does not close: an under-6 pediatric atopic dermatitis case, a weight-banded pen presentation that the local agent is not currently stocking, a denied biologic claim from Bupa Arabia or Tawuniya on the asthma or EoE indication, or a COPD case where the 2024 US label has not yet translated into local reimbursement. Reserve Meds coordinates the US-side sourcing, the cold-chain logistics, and the documentation packet your physician needs.
Reserved for you.
Why KSA patients need Dupixent through the named-patient pathway
The Kingdom of Saudi Arabia operates one of the most mature pharmaceutical regulatory frameworks in the Gulf Cooperation Council, and Saudi Vision 2030's Health Sector Transformation Program continues to invest heavily in dermatology, respiratory medicine, and pediatric subspecialty care. Dupixent sits on the SFDA register, and a KSA family asking for Dupixent is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to, or that their payer has declined to fund.
Four converging patterns drive these cases. First, indication lag. Newer Dupixent indications, especially pediatric atopic dermatitis under 6 years, pediatric EoE under 12 years, prurigo nodularis, and COPD with type 2 inflammation, often reach local registration 12 to 36 months after FDA approval. A family with a 3-year-old whose dermatologist has documented severe atopic dermatitis fits the US label but may not fit the current local label. Second, weight-banded pen presentations. A 25 kg child needing the 200 mg pen may find only the 300 mg pen on local shelves; local agents do not always carry every weight band reliably. Third, payer denial. Bupa Arabia, Tawuniya (The Company for Cooperative Insurance), and MedGulf Arabia each assess specialty biologics case by case, and type 2 inflammation indications often fail step-therapy or formulary coverage even when the drug is on the SFDA register. Cash-pay families pursue the cross-border route rather than wait through appeals at the Council of Cooperative Health Insurance (CCHI). Fourth, biosimilar substitution at the hospital pharmacy. Some institutions stock a non-Dupixent IL-4 or IL-13 agent and not the originator, leaving a patient whose specialist has named Dupixent specifically without a local route to that brand.
In each pattern, the SFDA PIP is the mechanism that connects an SCFHS-licensed physician's clinical decision with US-sourced, FDA-labeled Dupixent for a specific patient.
The SFDA Personal Importation Program for Dupixent
The Personal Importation Program allows an SCFHS-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognized reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable for the patient. The framework explicitly contemplates immunology, dermatology, respiratory, and pediatric specialty therapies. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector, increasingly routed through the Ghad digital regulatory platform at ghad.sfda.gov.sa.
A complete application includes a clinical justification letter from the treating physician (diagnosis with ICD-10 coding, severity, prior therapies attempted with outcomes, why a locally registered alternative is unsuitable, and the specific drug, dose, and duration requested), SCFHS registration verification in the relevant specialty (dermatology, pulmonology, allergy and immunology, gastroenterology, or pediatrics), an anonymized patient identifier linked to the hospital record, full product details (brand name, generic name, manufacturer, country of origin, strength, dosage form, pack size, requested quantity, lot, and expiry), the destination dispensing facility license, and a chain-of-custody plan from the US point of release through international transit with cold-chain validation to the receiving Saudi pharmacy.
For Dupixent specifically, the clinical justification angle typically rests on one of three documented elements. For a pediatric atopic dermatitis case under 6 years, the prescriber documents the FDA-approved age and weight indication and the local indication gap. For a denied biologic claim on asthma, EoE, COPD, or prurigo nodularis, the prescriber documents prior step-therapy failure and the type 2 inflammation phenotype (eosinophil count, IgE level, or biopsy finding where relevant). For a weight-banded pen request, the prescriber specifies the exact 100 mg, 150 mg, 200 mg, or 300 mg presentation required and the weight band that drives the choice. Note that Dupixent does not require tuberculosis screening as part of its FDA label, in contrast to IL-23 inhibitors and JAK inhibitors. The label does include a precaution for patients with helminth infection, which is relevant for patients with residency in endemic regions and forms part of the baseline workup.
Approval timelines for routine cases (recognized reference-authority drug, well-documented indication, established institution) typically run 10 to 21 business days. Complex cases (novel mechanism, first-time importer, unusual pen format) can extend to 6 to 10 weeks. SFDA does not publish guaranteed turnaround times, so case-by-case planning is the norm.
Where Dupixent gets dispensed in Saudi Arabia
The institutions that handle named-patient imports of cold-chain biologics as established workflow have both in-house import pharmacy infrastructure and 2 to 8 degrees Celsius storage with continuous monitoring. The set includes King Faisal Specialist Hospital and Research Centre (KFSH&RC) with its Riyadh, Jeddah, and Madinah operations and well-established immunology and dermatology programs; King Abdulaziz Medical City (KAMC) and the Ministry of National Guard Health Affairs network (MNGHA) in Riyadh and Jeddah; King Saud University Medical City (KSUMC) and the academic centers affiliated with King Saud bin Abdulaziz University for Health Sciences; Dr. Sulaiman Al Habib Medical Group (HMG) with its Riyadh, Jeddah, and Eastern Province facilities; Saudi German Health hospitals; Dr. Soliman Fakeeh Hospital in Jeddah; and Dallah Hospital in Riyadh.
For physicians at smaller hospitals without internal import pharmacy capacity, the practical route is to partner with an SFDA-licensed specialty importer based in Riyadh or Jeddah. The importer files the SFDA PIP application on the prescribing physician's behalf and transfers the medicine to the dispensing facility under the institutional license. Riyadh and Jeddah are the operational hubs; cases in the Eastern Province, Madinah, Tabuk, and Asir typically route through one of these two cities.
Real cost picture for Dupixent in Saudi Arabia
US WAC for Dupixent is approximately USD 3,993 per 300 mg pen carton (two-pack) as disclosed by Sanofi in January 2025, which translates to an annual WAC in the range of USD 37,000 to USD 43,000 for the most common adult atopic dermatitis regimen (300 mg every 2 weeks, 26 doses per year). The Saudi riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD, so the annual reference range converts to roughly SAR 139,000 to SAR 161,000 for the drug itself at US WAC equivalents.
International logistics for a cold-chain biologic shipment into the Kingdom typically runs USD 400 to USD 1,500 (approximately SAR 1,500 to SAR 5,600) depending on destination city, urgency, and pen-format pack size. SFDA permit fees and customs handling are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote, with no bundled or hidden line items.
On the insurance side, Bupa Arabia, Tawuniya, MedGulf Arabia, and other CCHI-regulated insurers each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked at a particular hospital. Many require pre-authorization with the clinical justification letter attached. Cash-pay is the default operating posture; reimbursement, where available, typically happens after delivery through the patient's own claim. The DUPIXENT MyWay copay card and US manufacturer patient assistance programs do not extend internationally.
Typical timeline for Dupixent in Saudi Arabia
SFDA routine processing is typically 10 to 21 business days from a complete filing. Cold-chain shipment adds 2 to 3 days versus an ambient small molecule because validated thermal packaging, continuous temperature monitoring, and customs clearance scheduled to avoid tarmac heat exposure in Riyadh and Jeddah are non-negotiable. End-to-end, most adult atopic dermatitis or asthma cases complete within 4 to 7 weeks from first complete documentation. Pediatric weight-banded cases and first-time importer pediatric pen formats may run slightly longer because the institutional and SFDA scrutiny extends. The 14-day room-temperature excursion runway on the FDA label gives meaningful operational flexibility, provided the cold chain is properly broken only at the dispensing pharmacy.
What your physician needs to provide
For an SCFHS-licensed dermatologist, pulmonologist, allergist, gastroenterologist, or pediatric specialist prescribing Dupixent through the PIP pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis with ICD-10 coding (atopic dermatitis with severity score, asthma with eosinophilic phenotype documented by blood eosinophil count, CRSwNP, EoE with biopsy confirmation, prurigo nodularis, or COPD with type 2 inflammation), prior therapy history including topical or systemic corticosteroids, prior biologics tried where relevant, and a clinical rationale for why dupilumab is the appropriate next step rather than a locally available alternative.
The letter specifies the exact dosing plan per the FDA-approved label: 600 mg load then 300 mg every 2 weeks for adult atopic dermatitis, weight-banded dosing for pediatric atopic dermatitis (200 mg or 300 mg every 4 weeks below 30 kg; 200 mg every 2 weeks for 30 to 60 kg; adult dosing at 60 kg and above), the asthma-specific regimen for moderate-to-severe asthma, 300 mg every 2 weeks for CRSwNP and COPD, and the weekly or every-other-week EoE schedule depending on age and weight. The monitoring plan should reference baseline helminth-infection assessment for patients from endemic regions, ophthalmology follow-up where conjunctivitis is a concern, and continuation of any background topical or inhaled therapy until the prescriber adjusts it.
The physician's SCFHS registration number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. The treating physician also commits, with the dispensing pharmacy, to reporting any adverse event through the SFDA National Pharmacovigilance Center for the full duration of therapy.
Common questions about Dupixent in Saudi Arabia
Will Bupa Arabia, Tawuniya, or MedGulf cover this? Each plan handles named-patient imports case by case. Some reimburse fully when Dupixent is on their formulary even if not stocked at a particular hospital. Many require pre-authorization with the clinical justification letter attached. Cash-pay is the default operating posture; reimbursement, where available, typically happens after delivery through the patient's own claim. We supply the documentation that allows the insurer to assess; the claim itself sits with you or your hospital.
My child is 4 years old. Is the under-6 indication accessible? The FDA approved Dupixent for atopic dermatitis in infants and young children 6 months and older in June 2022. The local KSA indication may lag the FDA timeline. The PIP pathway exists precisely to bridge this gap when the local label has not caught up.
My physician is at KFSH&RC in Riyadh. Do they have signing authority? Yes. SCFHS-licensed physicians at KFSH&RC, KAMC, MNGHA, KSUMC, HMG, Saudi German, Fakeeh, Dallah, and other major centers have full signing authority on PIP applications. The institutional pharmacy license then authorizes the dispensing facility to receive the imported drug.
Does Dupixent require TB screening like other biologics? No. The Dupixent FDA label does not require tuberculosis screening before initiation, in contrast to anti-TNF agents, IL-23 inhibitors such as Skyrizi and Stelara, and JAK inhibitors such as Rinvoq. The label does include a precaution for patients with known helminth infection, who should be treated before starting Dupixent. The treating physician makes the workup decision.
What about competitors like Adbry, Ebglyss, or oral JAK inhibitors? In atopic dermatitis, tralokinumab (Adbry) and lebrikizumab (Ebglyss) are alternative IL-13 pathway biologics, and JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib are oral alternatives. In asthma, omalizumab, mepolizumab, reslizumab, benralizumab, and tezepelumab sit in the same competitive set. Choice depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed.
Can I receive Dupixent at home? The dispensing facility must be a locally licensed Saudi pharmacy. The hospital outpatient pharmacy releases the pen to you after final verification, and you then administer the subcutaneous injection at home after training. The cold-chain handoff ends at the dispensing pharmacy; home refrigeration and injection-site rotation form part of your patient onboarding kit.
Where Reserve Meds fits in Dupixent cases
Reserve Meds is a US-based concierge coordinator. We do not replace your dermatologist, allergist, pulmonologist, or pediatrician, we do not replace SFDA, and we do not replace your dispensing pharmacy. For Dupixent specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits to the SFDA Personal Importation Program, coordinate validated cold-chain logistics with continuous temperature logging into Riyadh or Jeddah, and assign a single named coordinator through the case. No prior Reserve Meds case experience for Dupixent is logged yet; standard NPP coordination under our cold-chain biologic playbook applies. Pediatric pen selection, weight-banded dosing confirmation, and home-injection education are the recurring operational fundamentals we expect for this drug.
Next step
If your Saudi physician has prescribed Dupixent and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.